Search PubMed⌕ Search

PubMed · 9503879

Modeling two-state disease processes with random effects.

Abstract

Many chronic medical conditions are manifested by alternating sojourns in symptom-free and symptomatic states. In many cases, in addition to their relapsing and remitting nature, these conditions lead to worsening disease patterns over time and may exhibit seasonal trends. We develop a mixed-effect two-state model for such disease processes in which covariate effects are modeled multiplicatively on transition intensities. The transition intensities, in turn, are functions of three time scales: the semi-Markov scale involving the backward recurrence time for the cyclical component, the Markov scale for the time trend component, and a seasonal time scale. Multiplicative bivariate log-normal random effects are introduced to accommodate heterogeneity in disease activity between subjects and to admit a possible negative correlation between the transition intensities. Maximum likelihood estimation is carried out using Gauss-Hermite integration and a standard Newton-Raphson procedure. Tests of homogeneity are presented based on score statistics. An application of the methodology to data from a multi-center clinical trial of chronic bronchitis is provided for illustrative purposes.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

E T Ng, R J Cook. 1997. Modeling two-state disease processes with random effects.. https://doi.org/10.1023/a%3A1009650012039

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Determination of moxifloxacin in human plasma by liquid chromatography electrospray ionization tandem mass spectrometry.

Moxifloxacin is an advanced-generation, 8-methoxy fluoroquinolone that is active against a broad spectrum of pathogens, including antibiotic resistant Streptococcus pneumoniae. Development of a rapid, sensitive and selective method for the determination of moxifloxacin in human plasma is essential for understanding the pharmacokinetics of the drug when administered orally or intravenously. Solid phase extraction (SPE) using Oasis(R) HLB was used to extract moxifloxacin and the internal standard lomefloxacin from plasma. A method based on liquid chromatography electrospray ionization tandem mass spectrometry (LC/ESI-MS/MS) was developed and validated to quantitate moxifloxacin in human plasma. The precursor and major product ion of the analyte was monitored on a triple quadrupole mass spectrometer with positive ion electrospray ionization (ESI) in the multiple reaction monitoring (MRM) mode. Mechanisms for the formation of collision-induced dissociation (CID) products of moxifloxacin are proposed. Linear calibration curves were generated from 1 to 1000 ng/ml with coefficients of determination greater than 0.999. The inter-day and intra-day precision (% CV) was less than 11.3% and accuracy (% error) was less than 10.0% for moxifloxacin. The limit of detection (LOD) for the method was 50 pg/ml based on a signal to noise ratio of 3.

Anti-Infective Agents↗

Determination of the antibacterial ofloxacin in human urine and serum samples by solid-phase spectrofluorimetry.

A method for the determination of trace amounts of ofloxacin has been developed, based on solid-phase spectrofluorimetry. The relative fluorescence intensity of ofloxacin fixed on Sephadex SP C-25 gel was measured directly after packing the gel beads in a 1-mm silica cell, using a solid-phase attachment. The wavelengths of excitation and emission were 294 and 494 nm, respectively. The linear concentration range of application was 0.5-16.0 ng ml(-1) of ofloxacin, with a relative standard deviation of 1.1% (for a level of 8.0 ng ml(-1)) and a detection limit of 0.14 ng ml(-1). The method was applied to the determination of ofloxacin in human urine and serum samples. It was validated applying the standard addition methodology and using HPLC as a reference method. Recovery levels of the method reached 100% in all cases.

Anti-Infective Agents↗